The American College of Physicians Performance Measurement Committee reviewed the single MIPS quality measure tied to migraine and declined to support it, citing outdated guideline basis, missing exclusions, and lack of physician-level testing.

Blarcamesine (Anavex 2-73), an investigational once-daily oral autophagy enhancer, showed sustained cognitive, functional, and brain volume benefits through nearly 3 years in a Phase 2b/3 trial and open-label extension presented at AD/PD 2026.

A retrospective ADNI cohort analysis found that omega-3 supplement users showed faster cognitive decline over 5 years than matched non-users, with FDG-PET evidence of reduced brain glucose metabolism.

Late-breaking sessions at AAN 2026 spanned rare disease, migraine prevention, epilepsy, FTD, MS, early Alzheimer’s, neuropathic pain, and stiff person syndrome, with mixed signals across disease-modifying and symptomatic therapies.

Online wellness messaging is reframing nicotine pouches, gum, and patches as cognitive enhancers and dementia prevention tools, despite negative results from the larger MIND trial published in December 2025.

Multiple Alzheimer disease biomarkers showed accelerated age-related changes near age 70 in a Mayo Clinic Study of Aging cohort, identifying potential screening and monitoring windows.